Mark A. Dickson

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Purpose: The CDK4/6 inhibitor palbociclib delays progression in patients with advanced dedifferentiated liposarcoma (DDLPS). In carcinoma models, CDK4/6 and PD-1 inhibition induce intratumoral inflammation and synergistic activity. Comprehensive assessment of tumor and host dynamics is needed to understand response and resistance to this combination. Patients and Methods: We performed a phase 2 study of palbociclib and the PD-1 inhibitor retifanlimab in advanced DDLPS. Palbociclib was administered 2 weeks prior to retifanlimab. Tumor biopsies were analyzed by single-cell RNA sequencing (scRNA-seq), and peripheral blood by high-parameter flow cytometry. Analyses focused on cell cycle, senescence, and immune-related changes. Results: Twelve patients were treated before the study was halted because of a 42% immune-related toxicity rate. The overall response rate was 8.3%, and the disease control rate was 75%. Median progression-free and overall survival rates were 7.1 and 26.8 months, respectively. Nine patients had at least one tumor biopsy analyzed; three had paired. Ten patients had paired blood samples analyzed. Following treatment, tumor cells demonstrated decreased cycling and increased cell-cycle checkpoint activity. Transcriptional scores for senescence increased in cancer cells, as did the proportion of intratumoral T and B cells. A cluster of cells emerged with upregulated cell-cycle genes and downregulated HLA class I, suggesting innate or acquired resistance to treatment. In blood, a subset of CD4 + T cells decreased, whereas expression of LAG-3, ICOS, and CD38 increased in select subsets. Conclusions: A palbociclib lead-in prior to retifanlimab had a high rate of immune-related toxicities. Correlative analyses identified changes in tumor and immune cells attributable to treatment. A study of concurrent dosing of the combination is ongoing. Significance: In this phase 2 study of palbociclib and retifanlimab, treatment led to immune-related adverse events, halting enrollment. scRNA-seq and flow cytometry revealed cell-cycle suppression, senescence, and T-cell changes. These findings highlight the rationale for this combination and the need for safer dosing strategies in larger cohorts.

Year:

2026

Changes in tumor and immune cell populations and phenotypes with anti–PD-1. A, CDK4 and MDM2 expression in tumor cells according to best response. PD, P03, before and after retifanlimab initiation (IO); SD, three before IO and six after IO. B, Signature scores in tumor cells according to best response. Same samples as in A . C, Integrated clustering of cancer cells from patients with paired samples and sufficient tumor fraction. D and E, Intracluster signature score changes with initiation of retifanlimab, plotted ( D ) along the x -axis or ( E ) as dot size. F , Volcano plot of differential expression of genes related to immune response in cluster 8 vs. all other clusters from P12.

Year:

2026

Changes in proportions of T-cell populations with anti–PD-1 via high-parameter flow cytometry. A, Change in abundance of T-cell subtypes with initiation of retifanlimab in patients with paired biopsies and detectable tumor-infiltrating T cells. B, Boxplot depicting percent change post- vs. pre-retifanlimab in the abundance of 63 T cell types. Filled boxes with bold labels and asterisks indicate T cell subsets with significant changes ( P C and D, Percent change in four key subsets of ( C ) CD4 + and ( D ) CD8 + T cells. OR, overall response.

Year:

2026

Clinical trial design and efficacy. A, Study schema depicting treatment and biopsy collection time points. B, Flow diagram of treatment and follow-up for patients in the safety lead-in and trial expansion cohorts. C, Waterfall plot showing best percent tumor volume change from baseline per RECIST 1.1. One patient who was not evaluable for response by RECIST 1.1 is excluded. irAE(+), solid circles indicate irAEs; SC+, single-cell data from tumor biopsies, in which filling of the left and right halves indicates analyzability at the pre- and post-retifanlimab time points, respectively. D, Spider plot showing percent change in sum of target lesion diameters over time in patients who were evaluable for response by RECIST v1.1. E, Swimmer plot showing patient PFS. Dashed line indicates median PFS. NE, not evaluable; OR, overall response.

Year:

2026

Overview of scRNA-seq data. A, Cell clustering by UMAP. B, Expression of key markers within major cell populations, pooled among all specimens. C, Cell type proportion in each patient. Patients with paired biopsies were merged. D, Comparison of cell type proportions before vs. after retifanlimab initiation (IO) in patients with paired biopsies. UMAP, Uniform Manifold Approximation and Projection.

Year:

2026

Purpose: This study investigated factors that affected ctDNA detection and ctDNA as a molecular biomarker in a phase II trial of imatinib and binimetinib in newly diagnosed advanced gastrointestinal stromal tumor, including patients exposed to imatinib within 4 weeks of trial enrollment. Experimental Design: Plasma and tumor tissue samples were collected at baseline, during treatment, and upon progression. DNAs extracted from plasma and tumor tissue were analyzed using genomic assays, Memorial Sloan Kettering Analysis of Circulating cfDNA to Evaluate Somatic Status and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets, respectively. Sequenced ctDNA detection of the primary oncogenic driver was determined and correlated with clinical characteristics. Results: Patients ( n = 31) included in this analysis had KIT mutations ( n = 29, 94%) and metastatic disease ( n = 24, 77%) and achieved the best response of partial response ( n = 22, 71%), stable disease ( n = 8, 26%), or progressive disease ( n = 1, 3%). Sixteen patients (52%) were exposed to imatinib at baseline. The ctDNA detection rate of the primary oncogenic driver at baseline was 39% ( n = 12/31) and was significantly more likely in patients who were treatment-naïve ( n = 15) or had ≤4.2 weeks of treatment ( n = 8) than in those otherwise (48% vs. 13%; P value = 0.004). Baseline ctDNA detection did not correlate with tumor burden or stage. The ctDNA serial analysis of the primary oncogenic driver paralleled and sometimes preceded radiographic response. ctDNA detected resistance mutations in KIT ( n = 4). Active treatment influenced the detection of secondary KIT alterations in one patient. Conclusions: Active therapy at the time of ctDNA collection negatively affected the ability to detect primary and secondary KIT alterations in sequenced ctDNA from patients with advanced gastrointestinal stromal tumor. ctDNA responses may precede radiographic responses and merit further investigation.

Year:

2025

PURPOSE We hypothesized that ACR-368 (prexasertib) would be active in desmoplastic small round cell tumor (DSRCT) because of favorable responses in preclinical models. METHODS Preclinical work identified ACR-368 activity in DSRCT, and a phase I/II trial of ACR-368 and irinotecan in patients 12 months and older with relapsed/refractory DSRCT was conducted. The primary objectives were determination of recommended phase II dose (RP2D) and best overall response rate (ORR) at the RP2D in DSRCT, with ≥3 of 16 responses considered promising. RESULTS Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients were enrolled in a subsequent clinical trial. Treatment was well tolerated, and cytopenias were managed using growth factors. Fifteen of 19 patients, including five of six achieving PR, had previously received irinotecan. The estimated ORR at the RP2D was 23% (lower boundary one-sided 90% CI, 9%), exceeding the unpromising rate of 5%. In addition, three patients with DSRCT had a PR at doses other than the RP2D, bringing the ORR for all doses (n = 19) to 32% (90% CI, 15% to 53%). The median overall survival was 19 months (95% CI, 13 to 36). CONCLUSION The RP2D of ACR-368 with irinotecan by age group is ACR-368 105 or 150 mg/m 2 once on day 1 (>21 years or ≤21 years, respectively) and irinotecan 15 mg/m 2 once daily for 5 days in 21-day cycles for both groups. The study met its primary objective to consider ACR-368 and irinotecan promising in DSRCT and, to our knowledge, is the first incorporating a targeted therapy to achieve this magnitude of response.

Year:

2025

Supplementary Figure 1: Progression Free and Overall Survival in the Eligible and Treated Population (n=38) Kaplan Meier plots for progression free (A) and overall (B) survival in the eligible and treated population (n=38)

Year:

2025

Purpose: Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of the NCI-Molecular Analysis for Therapy Choice trial was designed to evaluate the CDK4/6 inhibitor palbociclib in CDK4- or CDK6-amplified tumors. Patients and Methods: Patients had a solid malignancy or lymphoma with progression on at least one systemic therapy for advanced disease or with no standard-of-care therapy available. Tumors with ≥7 copies of CDK4 or CDK6 were considered amplified and molecularly eligible. Enrolled patients were treated with palbociclib 125 mg daily on days 1 to 21 of a 28-day cycle. The primary endpoint was objective response rate. Results: Forty-three patients were enrolled on subprotocol Z1C, and 38 patients were deemed eligible, treated, and included in analyses; 25 patients were eligible, treated, and centrally confirmed to have CDK4 or CDK6 amplification and comprised the primary analysis cohort for objective response rate endpoint. Among the 25 patients in the primary cohort, one patient had a partial response, 4 patients had stable disease, and 16 patients had progressive disease as best response. Four patients were not evaluable due to lack of follow-up scans. Among the 38 evaluable patients, one patient had a partial response, 10 patients had stable disease, and 21 patients had progressive disease as best response. Partial response and stable disease were seen only in patients with CDK4 amplification. Median progression-free survival was 2.0 months, and median overall survival was 8.8 months. Conclusions: Palbociclib showed limited activity in histology-agnostic CDK4- or CDK6-amplified tumors, although central nervous system tumors may be worthy of future investigation.

Year:

2025

Purpose: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, which has modest activity in select sarcoma subtypes. Patients and Methods: This phase II study enrolled patients with advanced sarcoma into five cohorts including (i) undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma, (ii) liposarcoma (LPS), (iii) leiomyosarcoma (LMS), (iv) vascular sarcoma, including angiosarcoma and epithelioid hemangioendothelioma (EHE), and (v) other subtypes. Patients received epacadostat 100 mg twice daily plus pembrolizumab at 200 mg/dose every 3 weeks. The primary endpoint was best objective response rate (ORR), defined as complete response (CR) and partial response (PR), at 24 weeks by RECIST v.1.1. Results: Thirty patients were enrolled [60% male; median age 54 years (range, 24–78)]. The best ORR at 24 weeks was 3.3% [PR, n = 1 (leiomyosarcoma); two-sided 95% CI, 0.1%–17.2%]. The median PFS was 7.6 weeks (two-sided 95% CI, 6.9–26.7). Treatment was well tolerated. Grade 3 treatment-related adverse events occurred in 23% ( n = 7) of patients. In paired pre- and post-treatment tumor samples, no association was found between treatment and PD-L1 or IDO1 tumor expression or IDO-pathway–related gene expression by RNA sequencing. No significant changes in serum tryptophan or kynurenine levels were observed after baseline. Conclusions: Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (23)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Julia Glade Bender

Vice Chair for Clinical Research

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Samuel Singer

Vincent Astor Chair of Clinical Research

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Gerald Behr

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Angela DeMichele

University of Pennsylvania

UNITED STATES
View details

Raghu Kataru

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Nguan Soon Tan

Professor

Nanyang Technological University (NTU)

SINGAPORE
View details

Rodrigo Gularte Mérida

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Sam S. Yoon

-

UNITED STATES
View details

Andrew Kung

Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES
View details

Benjamin A Nacev

University of Pittsburgh

UNITED STATES
View details

Alex Kentsis

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Robert G. Maki

Professor, Member

-

UNITED STATES
View details

Jason Chan

Cedars-Sinai Medical Center

UNITED STATES
View details

Carlos L. Arteaga

University of Texas Southwestern Medical Center

UNITED STATES
View details

Ciara Kelly

-

UNITED STATES
View details

Marta Kovatcheva

Group Leader (Assistant Professor Equivalent)

IFOM – The AIRC Institute of Molecular Oncology

ITALY
View details

Andrew Koff

Sloan Kettering Institute

UNITED STATES
View details

Edmund Bartlett

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Violeta Serra

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details